Novartis Ag · SIX:NOVN
Novartis — Q3 2024 Earnings Presentation
72 slides from Novartis's earnings presentation, Oct 29, 2024
Slide 1: Q3 2024 Results
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Q3 2024 Results Q3 2024 Results Investor presentation Investor presentation October 29, 2024 October 29, 2024 Novartis Q3 Results | October 29, 2024 1
Slide 2: Disclaimer
Content Click below to navigate Disclaimer through the document Company overview This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” Financial re
Slide 3: Company overview
Content Click below to navigate through the document Company overview Financial review Conclusions Company Appendix References Company overview overview Vas Narasimhan, M.D. Vas Narasimhan, M.D. Chief Executive Officer Chief Executive Officer Novartis Q3 Results | October 29, 2024 3
Slide 4: Strong operational performance and key pipeline milestones in Q3
Content Click below to navigate Novartis delivered strong operational performance and key pipeline milestones in Q3, supporting a further upgrade to FY 2024 guidance through the document Company overview Financial review Conclusions Sales Core1 operating income Innovation highlights USD bn, % cc1 US
Slide 5: Q3 growth reflects strong performance from key growth drivers
GROWTH Content Click below to navigate Q3 growth reflects strong performance from key growth drivers as well as newer launches through the document Company overview Financial review Q3 sales Conclusions Sales Growth vs PY Growth vs PY USD million USD million cc Appendix 1,865 380 26% 1,693 364 28% R
Slide 6: Entresto sales continued to climb, +26% in Q3
GROWTH Content Click below to navigate Entresto® sales continued to climb, increasing +26% in Q3 through the document Company overview Financial review Sales evolution US weekly TRx1 Continued momentum in 10th year Conclusions USD m, % cc Total prescriptions (000) • US: +25% with TRx growth +20%; US
Slide 7: Cosentyx grew +28%, fueled by new launches
GROWTH Content Click below to navigate Cosentyx® grew +28%, fueled by new launches as well as expansion in core indications through the document Company overview Financial review Sales evolution Demand-driven growth across geographies Conclusions USD m, % cc • US: +38% US Ex-US • Ex-US: +16% cc Appe
Slide 8: Kesimpta continued to see strong demand globally
GROWTH Content Click below to navigate Kesimpta® continued to see strong demand globally through the document Company overview Financial review Sales evolution Continued market share gains in key geographies Conclusions USD m, % cc • >100k patients treated worldwide, majority naïve or first switch1
Slide 9: Kisqali cements leadership in mBC, launched in eBC
GROWTH Content Click below to navigate Kisqali® continued to cement leadership in mBC, and launched in eBC with FDA approval and Category 1 NCCN guideline recommendation through the document Company overview Financial review Sales evolution US: +50% growth, gaining widespread adoption Conclusions US
Slide 10: Kisqali shows deepening benefit in eBC
INNOVATION Content Click below to navigate Kisqali® shows deepening benefit in eBC, reducing the risk of recurrence by 28.5% in a broad population of patients1 through the document Company overview Financial review NATALEE 4-year data Conclusions IDFS benefit cross pre-specified subgroups1 Subgroup
Slide 11: Pluvicto steady performance post-taxane
GROWTH Content Click below to navigate Pluvicto® continued steady performance in the post-taxane setting, laying the foundation for anticipated PSMAfore launch in 2025 through the document Company overview ® Financial review Sales evolution Steady performance in Q3; Q4 expected to be broadly in line
Slide 12: Leqvio growth trend continued
GROWTH Content Click below to navigate Leqvio® growth trend continued, with accelerating adoption ex-US through the document Company overview Financial review Sales evolution US: Continued growth outpacing advanced lipid-lowering market1 Conclusions USD m, % cc • 4,600 facilities, accounting for 30%
Slide 13: Scemblix grew +72% in Q3
GROWTH Content Click below to navigate Scemblix® grew +72% in Q3 as the preferred option for 3L+ CML through the document Company overview Financial review Sales evolution Market leader in 3L+ NBRx and TRx across geographies Conclusions USD m, % cc • US: Leader in TRx (26%) and NBRx share, driven by
Slide 14: Fabhalta broad uptake in PNH
GROWTH Content Click below to navigate Fabhalta® continued to see broad uptake in PNH, as the only oral monotherapy providing comprehensive hemolysis control through the document Company overview Financial review PNH: Only oral monotherapy for adults with PNH providing comprehensive control of IVH a
Slide 15: Fabhalta accelerated approval in the US for IgAN
INNOVATION Content Click below to navigate Fabhalta® received accelerated approval in the US as first and only complement inhibitor for IgAN through the document Company overview Financial review Conclusions Received accelerated Increasing HCP Positive early launch approval from FDA preference momen
Slide 16: Iptacopan 12-month APPEAR-C3G data
INNOVATION Content Click below to navigate Iptacopan: 12-month APPEAR-C3G data presented at ASN1 support global regulatory filings by year-end 2024 through the document Company overview Financial review Change in UPCR2 - reduction sustained over 12 months Stabilization of eGFR3,4 - change in eGFR sl
Slide 17: Continued progress on innovation milestones in Q3
Content Click below to navigate Continued progress on innovation milestones in Q3 through the document Company overview 2024 selected key events (expected) Financial review H1 2024 H2 2024 Q3 status update Conclusions Regulatory Fabhalta® PNH EU, JP EU, JP and China approval in Q2 Appendix decisions
Slide 18: Financial review and 2024 guidance
Content Click below to navigate through the document Company overview Financial review Conclusions Financial review Appendix References Financial review and 2024 guidance and 2024 guidance Harry Kirsch Harry Kirsch Chief Financial Officer Chief Financial Officer Novartis Q3 Results | October 29, 202
Slide 19: Q3 net sales grew +10% cc with core operating income up +20%
FINANCIAL PROFILE Content Click below to navigate Q3 net sales grew +10% cc with core operating income up +20% cc1 through the document Company overview Financial review Continuing Operations1,2 Q3 Q3 Change vs PY 9M 9M Change vs PY Conclusions USD million 2023 2024 % USD % cc 2023 2024 % USD % cc A
Slide 20: Raising 2024 sales and core operating income guidance
FINANCIAL PROFILE Content Click below to navigate Raising 2024 sales and core operating income guidance1 Expected, barring unforeseen events; growth vs PY in cc1 through the document Company overview Financial review Conclusions Net sales Core operating income Appendix expected to grow expected to g
Slide 21: Continuing shareholder-friendly capital allocation strategy
FINANCIAL PROFILE Content Click below to navigate Continuing our shareholder-friendly capital allocation strategy through the document Company overview Financial review Conclusions Investing in the business Returning capital to shareholders Appendix Investments in organic business Consistently growi
Slide 22: Expected currency impact for 2024 and 2025
FINANCIAL PROFILE Content Click below to navigate Expected currency impact for full year 2024 and 2025 through the document Company overview Financial review Conclusions Appendix References 1. Constant currencies (cc), core results are non-IFRS measures. An explanation of non-IFRS measures can be fo
Slide 23: Conclusions
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Conclusions Conclusions Vas Narasimhan, M.D. Vas Narasimhan, M.D. Chief Executive Officer Chief Executive Officer Novartis Q3 Results | October 29, 2024 23
Slide 24: Continued strong business momentum in Q3
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Continued Raised FY 2024 Achieved important On track to strong business guidance for a indication achieve our momentum in Q3, third time expansions for mid-term guidance References with +10% n
Slide 25: Meet Novartis Management
Content Click below to navigate through the document Company overview Financial review Join us Join us in London for for Conclusions in London Meet Novartis Appendix References Meet Novartis Management Management November 20-21, 2024 November 20-21, 2024 Novartis Q3 Results | October 29, 2024 25
Slide 26: Appendix
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials References Appendix Appendix Novartis Q3 Results | October 29, 2024 26
Slide 27: Our pipeline projects at a glance
INNOVATION Content Click below to navigate Our pipeline projects at a glance through the document Company overview Financial review Phase 1/2 Phase 3 Registration Total Conclusions Oncology 27 8 5 40 Appendix Solid tumors 21 3 4 28 Innovation: Pipeline overview Hematology 6 5 1 12 Financial performa
Slide 28: Novartis pipeline in Phase 1
INNOVATION Content Click below to navigate Novartis pipeline in Phase 1 19 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) DFT383 DFT383 CTNS gene delivery Cystinosis pre/post kidney tran
Slide 29: Novartis pipeline in Phase 2
INNOVATION Content Click below to navigate Novartis pipeline in Phase 2 20 lead indications through the document Lead indication Company overview Oncology Immunology Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) CFZ533 iscalimab CD40 inhibitor Sjögren’s Solid tumors Financial r
Slide 30: Novartis pipeline in Phase 3
INNOVATION Content Click below to navigate Novartis pipeline in Phase 3 6 lead indications through the document Lead indication Company overview Oncology Neuroscience Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) BAF312 Mayzent® S1P1,5 receptor modulator Multiple sclerosis, ped
Slide 31: Novartis pipeline in registration
INNOVATION Content Click below to navigate Novartis pipeline in registration 1 lead indication through the document Company overview Oncology Code Name Mechanism Indication(s) Solid tumors Financial review AAA6011 Lutathera® Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumor
Slide 32: Novartis submission schedule: new molecular entities
INNOVATION Content Click below to navigate Novartis submission schedule New Molecular Entities: Lead and supplementary indications through the document Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2024 2025 2026 ≥2027 Conclusions atrasentan pelacarsen ia
Slide 33: Novartis submission schedule: existing brands
INNOVATION Content Click below to navigate Novartis submission schedule Supplementary indications for existing brands through the document Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2024 2025 2026 ≥2027 Conclusions Lutathera® Cosentyx® Cosentyx® Aimovi
Slide 34: Net debt increased by USD 6.1bn
Content Click below to navigate Net debt increased by USD 6.1bn due to the annual dividend, share buybacks and M&A, partially offset by FCF through the document Company overview Financial review USD bn -6.1 Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical
Slide 35: IR Clinical Studies
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Clinical Trials Update > C ardiovascular, Renal IR Clinical Studies and Metabolic > I mmunology > N euroscience
Slide 36: Cardiovascular, Renal and Metabolic
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Cardiovascular, Cardiovascular, Financial performance Innovation: Clinical trials Renal and Metabolic > C ardiovascular, Renal Renal and Metabolic and Metabolic >
Slide 37: atrasentan - ETA receptor antagonist
Content Click below to navigate atrasentan - ETA receptor antagonist through the document Company overview NCT04573478 ALIGN (CHK01-01) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 380 Primary Change in proteinuria Time Frame: Up to Week 24 or approximately 6 months
Slide 38: Fabhalta - CFB inhibitor
Content Click below to navigate Fabhalta® - CFB inhibitor Fabhalta® - CFB inhibitor through the document Company overview NCT04578834 APPLAUSE-IgAN (CLNP023A2301) NCT05755386 APPARENT (CLNP023B12302) Financial review Indication IgA nephropathy Indication Immune complex-mediated membranoproliferative
Slide 39: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT03705234 ORION-4 (CKJX839B12301) NCT05030428 VICTORION-2P (CKJX839B12302) Financial review Indication Hypercholesterolemia inc. Heterozygous Familial H
Slide 40: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT04652726 ORION-16 (CKJX839C12301) NCT04659863 ORION-13 (CKJX839C12302) Financial review Indication Hyperlipidemia, pediatrics Indication Hyperlipidemia
Slide 41: Leqvio - siRNA (regulation of LDL-C)
Content Click below to navigate Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) through the document Company overview NCT05739383 VICTORION-1P (CKJX839D12302) NCT05763875 V-Mono (CKJX839D12304) Financial review Indication CVRR (Primary prevention) Indication CVRR (Primary
Slide 42: pelacarsen - Antisense oligonucleotide targeting Lp(a)
Content Click below to navigate pelacarsen - Antisense oligonucleotide (ASO) through the document targeting Lp(a) Company overview NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Financial review Indication Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a) Con
Slide 43: zigakibart - Anti-APRIL
Content Click below to navigate zigakibart - Anti-APRIL through the document Company overview NCT05852938 BEYOND (CFUB523A12301) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 292 Appendix Primary Change in proteinuria [ Time Frame: 40 weeks or approximately 9 months
Slide 44: Immunology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Immunology > C ardiovascular, Renal Immunology and Metabolic > I mmunology > N euroscience > O ncology > I n-mar
Slide 45: Cosentyx - IL-17A inhibitor
Content Click below to navigate Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A inhibitor through the document Company overview NCT05767034 REPLENISH (CAIN457C22301) NCT04930094 GCAPTAIN (CAIN457R12301) Financial review Indication Polymyalgia rheumatica Indication Giant cell arteritis Phase Phase 3
Slide 46: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor Company overview NCT05126277 SIRIUS-LN (CVAY736K12301) Financial review Indication Lupus Nephritis Phase Phase 3 Conclusions Patients 420 Primary Outcome Frequency and percentage of parti
Slide 47: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor depletor Company overview NCT05349214 NEPTUNUS-2 (CVAY736A2302) NCT05350072 NEPTUNUS-1 (CVAY736A2301) Financial review Indication Sjögre
Slide 48: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor depletor Company overview NCT05639114 SIRIUS-SLE 1 (CVAY736F12301) NCT05624749 SIRIUS-SLE 2 (CVAY736F12302) Financial review Indication
Slide 49: LNA043 - ANGPTL3 agonist
Content Click below to navigate LNA043 - ANGPTL3 agonist through the document Company overview NCT04864392 ONWARDS (CLNA043A12202) Financial review Indication Knee osteoarthritis Phase Phase 2 Conclusions Patients 576 Primary Change from baseline in the cartilage thickness of the medial compartment
Slide 50: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor through the document Company overview NCT05030311 REMIX-1 (CLOU064A2301) NCT05032157 REMIX-2 (CLOU064A2302) Financial review Indication Chronic spontaneous urticaria Indication Chronic spontaneous urticaria Pha
Slide 51: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor through the document Company overview NCT05976243 (CLOU064M12301) Financial review Indication Chronic inducible urticaria Phase Phase 3 Conclusions Patients 348 Primary 1. Proportion of participants with complete response in Total Fric Sco
Slide 52: Neuroscience
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Neuroscience > C ardiovascular, Renal Neuroscience and Metabolic > I mmunology > N euroscience > O ncology > I n
Slide 53: Mayzent - S1P1,5 receptor modulator
Content Click below to navigate Mayzent® - S1P1,5 receptor modulator through the document Company overview NCT04926818 NEOS (CBAF312D2301) Financial review Indication Multiple sclerosis, pediatrics Phase Phase 3 Conclusions Patients 120 Primary Annualized relapse rate (ARR) in target pediatric parti
Slide 54: remibrutinib - BTK inhibitor
Content Click below to navigate remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor through the document Company overview NCT05147220 REMODEL-1 (CLOU064C12301) NCT05156281 REMODEL-2 (CLOU064C12302) Financial review Indication Multiple sclerosis Indication Multiple sclerosis Phase Phase 3 Phase
Slide 55: Zolgensma - SMN1 gene replacement therapy
Content Click below to navigate Zolgensma® - SMN1 gene replacement therapy Zolgensma® - SMN1 gene replacement therapy through the document Company overview NCT05089656 STEER (COAV101B12301) NCT05386680 STRENGTH (COAV101B12302) Financial review Indication Spinal muscular atrophy (IT administration) I
Slide 56: Iptacopan - CFB inhibitor
Content Click below to navigate Iptacopan - CFB inhibitor through the document Company overview CLNP023Q12301 Financial review Indication Generalized Myasthenia Gravis Phase Phase 3 Conclusions Patients 146 Primary Change from baseline to Month 6 Appendix in Myasthenia Gravis Activity of Outcome Mea
Slide 57: Oncology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Oncology > C ardiovascular, Renal Oncology and Metabolic > I mmunology > N euroscience > O ncology > I n-market
Slide 58: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor depletor Company overview NCT05653349 VAYHIT1 (CVAY736I12301) NCT05653219 VAYHIT2 (CVAY736Q12301) Financial review Indication 1L Immune
Slide 59: ianalumab - BAFF-R inhibitor
Content Click below to navigate ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell through the document depletor Company overview NCT05648968 VAYHIA (CVAY736O12301) Financial review Indication Warm autoimmune hemolytic anemia Phase Phase 3 Conclusions Patients 90 Primary Binary variable indicating w
Slide 60: iptacopan - CFB inhibitor
Content Click below to navigate iptacopan - CFB inhibitor through the document Company overview NCT04889430 APPELHUS (CLNP023F12301) Financial review Indication Atypical haemolytic uraemic syndrome Phase Phase 3 Conclusions Patients 50 Primary Percentage of participants with complete TMA response wi
Slide 61: Pluvicto - Radioligand therapy target PSMA
Content Click below to navigate Pluvicto® - Radioligand therapy target PSMA Pluvicto® - Radioligand therapy target PSMA through the document Company overview NCT04689828 PSMAfore (CAAA617B12302) NCT04720157 PSMAddition (CAAA617C12301) Financial review Indication Metastatic castration-resistant prost
Slide 62: Rydapt - Multi-targeted kinase inhibitor
Content Click below to navigate Rydapt® - Multi-targeted kinase inhibitor through the document Company overview NCT03591510 (CPKC412A2218) Financial review Indication Acute myeloid leukemia, pediatrics Phase Phase 2 Conclusions Patients 20 Primary Occurrence of dose limiting toxicities Appendix Outc
Slide 63: Scemblix - BCR-ABL inhibitor
Content Click below to navigate Scemblix® - BCR-ABL inhibitor through the document Company overview NCT04971226 ASC4FIRST (CABL001J12301) Financial review Indication Chronic myeloid leukemia, 1st line Phase Phase 3 Conclusions Patients 402 Primary Major Molecular Response (MMR) at week 48 Appendix O
Slide 64: Vijoice - PI3Ki
Content Click below to navigate Vijoice® - PI3Ki through the document Company overview NCT05948943 EPIK-L1 (CBYL719P12201) Financial review Indication Lymphatic Malformation Phase Phase 2/3 Conclusions Patients 230 Primary Outcome Stage 2: Radiological response rate at Week 24 of Stage 2 (adult and
Slide 65: In-market Brands & Global Health
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview In-market Brands In-market Brands Financial performance Innovation: Clinical trials & Global Health > C ardiovascular, Renal & Global Health and Metabolic > I mmu
Slide 66: Beovu - VEGF Inhibitor
Content Click below to navigate Beovu® - VEGF Inhibitor through the document Company overview NCT04278417 CONDOR (CRTH258D2301) Financial review Indication Diabetic retinopathy Phase Phase 3 Conclusions Patients 694 Primary Change from Baseline in BCVA Appendix Outcome Innovation: Pipeline overview
Slide 67: cipargamin - PfATP4 inhibitor
Content Click below to navigate cipargamin - PfATP4 inhibitor through the document Company overview NCT04675931 KARISMA (CKAE609B12201) Financial review Indication Malaria severe Phase Phase 2 Conclusions Patients 252 Primary Percentage of participants achieving at least 90% reduction in Plasmodium
Slide 68: Coartem - Artemisinin combination therapy
Content Click below to navigate Coartem® - Artemisinin combination therapy through the document Company overview NCT04300309 CALINA (CCOA566B2307) Financial review Indication Malaria, uncomplicated (<5kg patients) Phase Phase 3 Conclusions Patients 44 Primary Artemether Cmax Appendix Outcome Innovat
Slide 69: ganaplacide/lumefantrine - Non-artemisinin inhibitor
Content Click below to navigate ganaplacide/lumefantrine - Non-artemisinin through the document plasmodium falciparum inhibitor Company overview NCT05842954 KALUMA (CKLU156A12301 ) Financial review Indication Malaria, uncomplicated Phase Phase 3 Conclusions Patients 1500 Primary PCR-corrected adequa
Slide 70: References 1/3
Content Click below to navigate References 1/3 through the document Company overview Entresto® (slide 6 references) Financial review 1 IQVIA National Prescription Audit. 2 AHA/ACC/HFSA/ESC. Conclusions Approved indications differ by geography. Examples include “indicated to reduce the risk of cardio
Slide 71: References 2/3
Content Click below to navigate References 2/3 through the document Company overview Kisqali® (slide 10 references) Financial review Fasching PA. Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase Inhibitor (NSAI) in Patients (Pts) With HR+/HER2− Early Breast Cancer (EBC): 4-Year Outcomes From th
Slide 72: References 3/3
Content Click below to navigate References 3/3 through the document Company overview Fabhalta® (slide 15 references) Financial review 1 United BioSource LLC. Generally, a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g. Conclusions Iptacopan (slide 16 references) Appendix 1 ASN 2024 presentation S